TIGIT enhances CD4+ regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model

• Published in: Cancer medicine (Malden, MA) Vol. 9; no. 10; pp. 3584 - 3591
• Main Authors: Chen, Fengzhen, Xu, Yanying, Chen, Yulong, Shan, Shu
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.05.2020; John Wiley and Sons Inc; Wiley
• Subjects: Antibodies; Apoptosis; Ascites; Cancer Biology; Cancer therapies; CD4 antigen; CD8 antigen; Cell activation; Chemotherapy; Cloning; Enzymes; Experiments; Flow cytometry; Immune checkpoint; Immunoglobulins; Immunoregulation; Immunosuppression; Laboratory animals; Lymphocytes; Lymphocytes T; Medical prognosis; Monoclonal antibodies; Natural killer cells; Original Research; Ovarian cancer; regulatory T cell; Spleen; Therapeutic applications; TIGIT; Tumors; immunosuppression; regulatory T cell; TIGIT; ovarian cancer

Ovarian cancer (OC) is the fifth‐leading cause of cancer‐related death in women with a pathogenesis involving activation of regulatory T cells (Tregs). The T‐cell immunoglobulin and ITIM domain (TIGIT) is a well‐known immune checkpoint molecule that inhibits T‐cell responses. However, the role of TI...